![Douglas Fambrough](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Douglas Fambrough
Direttore/Membro del Consiglio presso
Anjarium Biosciences AG
Profilo
Douglas McIntosh Fambrough was the founder of Dicerna Pharmaceuticals, Inc., founded in 2007, where the title held was President, Chief Executive Officer & Director from 2010 to 2021.
Current jobs include Non-Executive Director at Anjarium Biosciences AG since 2022, Independent Director at Switch Therapeutics, Inc. since 2023, Non-Executive Director at Sirius Therapeutics since 2022, and Portfolio Manager at KCap Biotechnology Fund LP.
Former jobs include Director at Sirna Therapeutics, Inc. from 2003 to 2006, Director at Xencor, Inc., Solstice Neurosciences, Inc., Melinta Subsidiary Corp., Solexa, Inc., and Oncorus, Inc. from 2022 to 2023, Independent Director at TScan Therapeutics, Inc. from 2020 to 2021, General Partner at Oxford Bioscience Partners from 1999 to 2010, and Trustee at The Boston Biomedical Research Institute.
Education includes a doctorate from the University of California, Berkeley in 1996 and an undergraduate degree from Cornell University in 1991.
Posizioni attive di Douglas Fambrough
| Società | Posizione | Inizio |
|---|---|---|
Anjarium Biosciences AG
 Anjarium Biosciences AG BiotechnologyHealth Technology Develops non-viral gene therapy | Direttore/Membro del Consiglio | 18/10/2022 |
Switch Therapeutics, Inc.
 Switch Therapeutics, Inc. BiotechnologyHealth Technology Develops precision RNA interference medicines for central nervous system diseases | Direttore/Membro del Consiglio | 10/07/2023 |
Precedenti posizioni note di Douglas Fambrough
| Società | Posizione | Fine |
|---|---|---|
| ONCORUS, INC. | Direttore/Membro del Consiglio | 20/07/2023 |
| DICERNA PHARMACEUTICALS, INC. | Fondatore | 28/12/2021 |
| TSCAN THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 01/03/2021 |
Sirna Therapeutics, Inc.
 Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Provides and develops pharmaceutical products | Direttore/Membro del Consiglio | 29/12/2006 |
Solexa, Inc.
 Solexa, Inc. Pharmaceuticals: OtherHealth Technology Creates DNA cloning and analyses technologies | Direttore/Membro del Consiglio | 28/08/2006 |
Formazione di Douglas Fambrough
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
78
Relazioni di 1° grado
14
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 14 |
|---|---|
Sirna Therapeutics, Inc.
Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Provides and develops pharmaceutical products | Commercial Services |
Oxford Bioscience Partners
 Oxford Bioscience Partners Investment ManagersFinance Oxford Bioscience Partners (OBP) focuses on investments in emerging, entrepreneurial-driven companies in the life sciences and healthcare sectors. They look for companies in the medical devices, R&D instruments and systems and therapeutics industries and for companies with breakthrough life sciences technology. The firm also invests in non-life science based technologies that have novel healthcare applications. OBP considers investments at almost any stage, but they place emphasis on early-stage opportunities. Investments range from $1 million to $10 million, but they may also make smaller seed investments in certain situations. OBP acts as the lead investor to organize an appropriate syndicate of co-investors. They consider investments in almost all geographic locations. | Finance |
Xencor, Inc.
 Xencor, Inc. BiotechnologyHealth Technology Develops therapeutics to treat autoimmune and allergic diseases, cancer and other conditions | Health Technology |
Solstice Neurosciences, Inc.
 Solstice Neurosciences, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures, sells and markets biopharmaceutical products | Health Technology |
Dicerna Pharmaceuticals, Inc.
 Dicerna Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that focuses on discovering, developing and commercializing medicines for chronic liver diseases | Health Technology |
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Berkeley
 University of California, Berkeley Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Melinta Subsidiary Corp.
 Melinta Subsidiary Corp. Pharmaceuticals: MajorHealth Technology Develops and markets pharmaceutical products for the treatment of life-threatening infections | Health Technology |
Solexa, Inc.
Solexa, Inc. Pharmaceuticals: OtherHealth Technology Creates DNA cloning and analyses technologies | Health Technology |
The Boston Biomedical Research Institute | |
Oncorus, Inc.
 Oncorus, Inc. BiotechnologyHealth Technology Operates as biotechnology company that develops next generation immunotherapy platform to treat cancer | Health Technology |
TScan Therapeutics, Inc.
 TScan Therapeutics, Inc. BiotechnologyHealth Technology Develops T-cell therapies for cancer patients | Health Technology |
Anjarium Biosciences AG
Anjarium Biosciences AG BiotechnologyHealth Technology Develops non-viral gene therapy | Health Technology |
Switch Therapeutics, Inc.
Switch Therapeutics, Inc. BiotechnologyHealth Technology Develops precision RNA interference medicines for central nervous system diseases | Health Technology |
